Summit Therapeutics Inc. - Common Stock (SMMT)

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.

Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Last week's top performers: SMMT, HMY, AU, CVNA, HOOD, NEM, AVGO, GFI, KGC, CEG. Are they in your portfolio? #stockmarket #investing